The effect of 1 year of trilostane treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent hyperadrenocorticism
2016
Oda, H. (Nippon Veterinary and Life Science University, Musashino, Tokyo (Japan). Faculty of Veterinary Science, School of Veterinary Nursing and Technology) | Mori, A. | Shono, S. | Onozawa, E. | Sako, T.
This study investigated the changes in lymphocyte subsets during the trilostane medication of Pituitary-dependent hyperadrenocorticism (PDH) dogs. The cortisol level and lymphocyte subsets of eight dogs with PDH were monitored 0, 1, 3, 6, 9 and 12 months after the initiation of trilostane treatment. White blood cells (WBC), lymphocytes, CD3sup(+) (T lymphocyte), CD4sup(+) (helper T lymphocyte), CD8sup(+) (cytotoxic T lymphocyte) and CD21sup(+) (B lymphocyte) cells were measured. Although the post-ACTH stimulation test cortisol level was significantly lower during trilostane treatment, changes in the CD3sup(+), CD4sup(+), CD8sup(+), and CD21sup(+), counts were not observed. Meanwhile, significant decrease was observed in WBC counts during trilostane treatment. These indicate that long-term trilostane treatment has little effect on the lymphocyte subsets in PDH dogs.
اظهر المزيد [+] اقل [-]